ABEONA THERAPEUT. DL-01 (PCJ) - Total Liabilities
Based on the latest financial reports, ABEONA THERAPEUT. DL-01 (PCJ) has total liabilities worth €60.35 Million EUR (≈ $70.56 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore PCJ year-over-year net asset growth to track the company's year-over-year net asset growth rate.
ABEONA THERAPEUT. DL-01 - Total Liabilities Trend (2021–2025)
This chart illustrates how ABEONA THERAPEUT. DL-01's total liabilities have evolved over time, based on quarterly financial data.
ABEONA THERAPEUT. DL-01 Competitors by Total Liabilities
The table below lists competitors of ABEONA THERAPEUT. DL-01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Selena FM S.A.
WAR:SEL
|
Poland | zł667.99 Million |
|
Taiga Building Products Ltd.
TO:TBL
|
Canada | CA$284.53 Million |
|
China Western Power Industrial Co Ltd
SHE:002630
|
China | CN¥8.67 Billion |
|
Jiang Su New Technology Co. Ltd.
SHE:301229
|
China | CN¥563.13 Million |
|
Vátryggingafélag Íslands hf
IC:SKAGI
|
Iceland | Ikr44.30 Billion |
|
Guangdong Kitech New Material Holding Co.Ltd.
SHE:300995
|
China | CN¥182.85 Million |
|
Anton Oilfield Services Group
F:5AO
|
Germany | €7.83 Billion |
|
Eaton Vance Floating Rate Income Closed Fund
NYSE:EFT
|
USA | $194.26 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ABEONA THERAPEUT. DL-01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of ABEONA THERAPEUT. DL-01.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ABEONA THERAPEUT. DL-01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ABEONA THERAPEUT. DL-01 (2021–2025)
The table below shows the annual total liabilities of ABEONA THERAPEUT. DL-01 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €60.35 Million ≈ $70.56 Million |
-7.00% |
| 2024-12-31 | €64.90 Million ≈ $75.87 Million |
+31.97% |
| 2023-12-31 | €49.18 Million ≈ $57.49 Million |
+31.30% |
| 2022-12-31 | €37.45 Million ≈ $43.79 Million |
+0.63% |
| 2021-12-31 | €37.22 Million ≈ $43.51 Million |
-- |
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more